

2020

英文論文

1. 2020 Cheng AL, Hsu C, Chan SL, Choo SP, **Kudo M**: Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. **J Hepatol** 72:307-319, 2020(IF=20.582).
2. 2020 Sakurai T, Nishiyama H, Nagai T, Goto S, Ogata H, **Kudo M**: Deficiency of Gankyrin in the small intestine is associated with augmented colitis accompanied by altered bacterial composition of intestinal microbiota. **BMC Gastroenterol** 20:12, 2020(IF=2.489).
3. 2020 Matsui S, Kashida H, Nomura K, Komeda Y, **Kudo M**: Multiple gastrointestinal stromal tumors of the duodenum associated with neurofibromatosis type. **Advanced Research in Gastroenterol & Hepatol (ARGH)** 14, 2020 (doi: 10.0.74.136/ARGH.2020.14.555889) (IF=0.778).
4. 2020 Takashima K, Matsui S, Komeda Y, Nagai T, Sakurai T, Kashida H, **Kudo M**: Endoscopic sclerotherapy under balloon-assisted enteroscopy for hemorrhagic jejunal varices after choledocho-jejunosotomy. **Endoscopy**; E41-E42, 2020. doi: 10.1055/a-0987-9780(IF=7.341).
5. 2020 **Kudo M***: Management of hepatocellular carcinoma in Japan: Current trends. **Liver Cancer** 9:1-5, 2020(IF=9.720).
6. 2020 Alsina A, **Kudo M**, Vogel A, Cheng AL, Tak WY, Ryoo BY, Evans TRJ, López López C, Daniele B, Misir S, Ren M, Izumi N, Qin S, Finn RS: Effects of subsequent systemic anticancer medication following first-line lenvatinib: A post hoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma. **Liver Cancer** 9:93-104, 2020(IF=9.720).
7. 2020 Morita M, Ogawa C, Omura A, Noda T, Kubo A, Matsunaka T, Tamaki H, Shibatoge M, Seno H, Minami Y, Ueshima K, Sakurai T, Nishida N, **Kudo M***: The efficacy of Sonazoid-enhanced

2020

英文論文

- ultrasonography in decision-making for liver abscess treatment. **Intern Med** 59:471-477, 2020(IF=1.005).
8. 2020 Kanemura H, Hayashi H, Hagiwara S, Otani T, Haratani K, Yonesaka K, Ito A, **Kudo M**, Nakagawa K: Severe immune-related hepatitis treated with plasma exchange. **J Thorac Oncol** 15:e39-e42, 2020(IF=13.357).
 9. 2020 Aoki T, Kubota K, Hasegawa K, Kubo S, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Nakashima O, Matsuyama Y, Murakami T, **Kudo M**, Liver Cancer Study Group of Japan: Significance of the surgical hepatic resection margin in patients with a single hepatocellular carcinoma. **Br J Surg** 107:113-120, 2020(IF=5.676).
 10. 2020 Aoki T, Kubota K, Kubo S, **Kudo M**: Author response to: comment on: "Significance of the surgical hepatic resection margin in patients with a single hepatocellular carcinoma". **Br J Surg** 107:465, 2020(IF=5.676).
 11. 2020 Aoki T, Kubota K, Kubo S, **Kudo M**: Author response to: comment on: "Significance of the surgical hepatic resection margin in patients with a single hepatocellular carcinoma". **Br J Surg** 107:470, 2020(IF=5.676).
 12. 2020 Sofue K, Onoda M, Tsurusaki M, Morimoto D, Yada N, **Kudo M**, Murakami T: Dual-frequency MR elastography to differentiate between inflammation and fibrosis of the liver: Comparison with histopathology. **J Magn Reson Imaging** 51:1053-1064, 2020(IF=3.954).
 13. 2020 Minaga K, Takenaka M, Yamao K, Kamata K, Omoto S, Nakai A, Yamazaki T, Okamoto A, Ishikawa R, Yoshikawa T, Chiba Y, Watanabe T, **Kudo M**: Clinical utility of treatment method conversion during single-session endoscopic ultrasound-guided biliary drainage. **World J Gastroenterol** 26:947-959,

2020

英文論文

2020(IF=3.665).

14. 2020 Hiraoka A, Kumada T, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Yokohama K, Nouse K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K, **Kudo M**, on behalf of the Real-Life Practice Experts for HCC (RELPEC) study group and HCC 48 Group: Post-progression treatment eligibility of unresectable hepatocellular carcinoma patients treated with lenvatinib. **Liver Cancer** 9:73-83, 2020(IF=9.720).
15. 2020 Cucchetti A, Zhong J, Berhane S, Toyoda H, Shi K, Tada T, Chong CCN, Xiang BD, Li LQ, Lai PBS, Ercolani G, Mazzaferro V, **Kudo M**, Cescon M, Pinna AD, Kumada T, Johnson PJ: The chances of hepatic resection curing hepatocellular carcinoma. **J Hepatol** 72:711-717, 2020(IF=20.582).
16. 2020 Finn RS, Ryoo BY, Merle P, **Kudo M**, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yao T, Garrido M, Chan SL, Knox J, Daniele B, Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL, for the KEYNOTE-240 investigators: Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase 3 trial. **J Clin Oncol** 38:193-202, 2020(IF=32.956).
17. 2020 Yamao K, Watanabe T, **Kudo M**: Response to the letter to the editor 'Reply to "Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrospective Study" by Dr. Peng Chen'. **Intern Med** 59:879, 2020(IF=1.005).
18. 2020 Yamashita T, **Kudo M**, Ikeda K, Izumi N, Tateishi R, Ikeda M, Aikata H, Kawaguchi Y, Wada Y, Numata K, Inaba Y, Kuromatsu

2020

英文論文

- R, Kobayashi M, Okusaka T, Tamai T, Kitamura C, Saito K, Haruna K, Okita K, Kumada H: REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. **J Gastroenterol** 55:113-122, 2020(IF=6.132).
19. 2020 Takenaka M, Minaga K, Kamata K, Yamao K, Yoshikawa T, Ishikawa R, Okamoto A, Yamazaki T, Nakai A, Omoto S, Komeda Y, Sakurai T, Watanabe T, Nishida N, Kwon C, Jeong S, Lee TH, **Kudo M**: Efficacy of a modified double-guidewire technique using an uneven double lumen cannula (uneven method) in patients with surgically altered gastrointestinal anatomy (with video). **Surg Endosc** 34:1432-1441, 2020(IF=3.149).
20. 2020 **Kudo M***, Izumi N, Kubo S, Kokudo N, Sakamoto M, Shiina S, Tateishi R, Nakashima O, Murakami T, Matsuyama Y, Takahashi A, Miyata H, Takayama T: Report of the 20th nationwide follow-up survey of primary liver cancer in Japan. **Hepatol Res** 50:15-46, 2020(IF=3.165).
21. 2020 Minami Y, Minami T, Chishina H, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, **Kudo M***: Radiofrequency ablation for hepatocellular carcinoma: clinical value of ultrasound-ultrasound overlay fusion for optimal ablation and local controllability. **Hepatol Res** 50:67-74, 2020(IF=3.165).
22. 2020 Yamamoto N, Ryoo BY, Keam B, **Kudo M**, Lin CC, Kunieda F, Ball H, Moran D, Komatsu K, Takeda K, Fukuda M, Furuse J, Morita S, Doi T: A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies. **Invest New Drugs** 38:445-456, 2020(IF=3.525).
23. 2020 **Kudo M***: Scientific rationale for combined immunotherapy with PD-1/PD-L1 antibodies and VEGF inhibitors in advanced

2020

英文論文

- hepatocellular carcinoma. **Cancers** 12: E1089, 2020, doi:10.3390/cancers12051089(IF=6.126).
24. 2020 Minaga K, Takenaka M, Okamoto A, Omoto S, Kamata K, Yamao K, **Kudo M**: Revisionary anti-reflux metal stent placement for stent occlusion after endoscopic ultrasound-guided hepaticojejunostomy. **Endoscopy** 52:E152-E153, 2020(IF=7.341).
25. 2020 Minaga K, Watanabe T, Arai Y, Shiokawa M, Hara A, Yoshikawa T, Kamata K, Yamashita K, **Kudo M**: Activation of interferon regulatory factor 7 in plasmacytoid dendritic cells promotes experimental autoimmune pancreatitis. **J Gastroenterol** 55:565-576, 2020(IF=6.132).
26. 2020 Watanabe Y, Matsuyama Y, Izumi N, Kubo S, Kokudo N, Sakamoto M, Shiina S, Takayama T, Nakashima O, **Kudo M**: Effect of surgical margin width after R0 resection for intrahepatic cholangiocarcinoma: A nationwide survey of the Liver Cancer Study Group of Japan. **Surgery** 167:793-802, 2020(IF=3.356).
27. 2020 Hiraoka A, Kumada T, Tada T, Fukunishi S, Atsukawa M, Hirooka A, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Toyoda H, Ohama H, Tsutsui A, Itokawa N, Hayama K, Arai T, Imai M, Nakamura S, Michitaka K, Hiasa Y, **Kudo M**, Real-Life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group: Nutritional index as prognostic indicator in patients receiving lenvatinib treatment for unresectable hepatocellular carcinoma. **Oncology** 98:295-302, 2020(IF=2.642).
28. 2020 Minami Y, **Kudo M**: Ultrasound fusion imaging technologies for guidance in ablation therapy for liver cancer. **J Med Ultrason** 47:257-263, 2020(IF=0.898).
29. 2020 Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, **Kudo M**,

2020

英文論文

- Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL: Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. **New Engl J Med** 382:1894-1905, 2020(IF=74.699).
30. 2020 **Kudo M***: A new era in systemic therapy for hepatocellular carcinoma: Atezolizumab plus bevacizumab combination therapy. **Liver Cancer** 9:119-137, 2020(IF=9.720).
31. 2020 Hack SP, Spahn J, Chen M, Cheng AL, Kaseb A, **Kudo M**, Lee HC, Yopp A, Chow P, Qin S: IMbrave050: a phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. **Future Oncol** 16:975-989, 2020(IF=2.660).
32. 2020 Nishida N, **Kudo M**: Immune phenotype and immune checkpoint inhibitors for the treatment of human hepatocellular carcinoma. **Cancers** 12:E1274, 2020. doi: 10.3390/cancers12051274(IF=6.126).
33. 2020 Yoo C, Oh DY, Choi HJ, **Kudo M**, Ueno M, Kondo S, Chen LT, Osada M, Helwig C, Dussault I, Ikeda M: Phase 1 study of bintrafusp alfa, a bifunctional fusion protein targeting TGF- β and PD-L1, in patients with pretreated biliary tract cancer. **J Immunother Cancer** 8:e000564, 2020(IF=9.913).
34. 2020 Piscaglia F, Stefanini F, Cantisani V, Sidhu PS, Barr R, Berzigotti A, Chammas MC, Correas JM, Dietrich CF, Feintstein S, Huang P, Jenssen C, Kono Y, **Kudo M**, Liang P, Lyshchik A, Nolsoe C, Xie X, Tovoli F: Benefits, open questions and challenges of the use of ultrasound in the COVID-19 pandemic era. The views of a panel of worldwide international experts. **Ultraschall in Med** 41:228-236, 2020(IF=4.966).
35. 2020 **Kudo M**, Okusaka T, Motomura K, Ohno I, Morimoto M, Seo S, Wada Y, Sato S, Yamashita T, Furukawa M, Aramaki T, Nadano

2020

英文論文

- S, Ohkawa K, Fujii H, Kudo T, Furuse J, Takai H, Homma G, Yoshikawa R, Zhu AX: Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial. **J Gastroenterol** 55:627-639, 2020(IF=6.132).
36. 2020 Takenaka M, Nakai A, **Kudo M**: Novel concept of bared type metallic stent for endoscopic bilateral stent-in-stent placement in patients with hilar malignant biliary obstruction (with video). **J Hepato-Bil-Pan Sci** 27:282-283, 2020(IF=4.160).
37. 2020 **Kudo M***: Better efficacy of ramucirumab in Japanese patients than in the global population with unresectable hepatocellular carcinoma. **Liver Cancer** 9:232-244, 2020(IF=9.720).
38. 2020 **Kudo M***, Han KH, Ye SL, Zhou J, Huang YH, Lin SM, Wang CK, Ikeda M, Chan SL, Choo SP, Miyayama S, Cheng AL, on behalf of the APPLC Association: A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: Asia-Pacific primary liver cancer expert consensus statements. **Liver Cancer** 9:245-260, 2020(IF=9.720).
39. 2020 Yamakawa M, Shiina T, Nishida N, **Kudo M**: Optimal cropping for input images used in a convolutional neural network for ultrasonic diagnosis of liver tumor. **Jpn J Appl Phys** 59:SKKE09, 2020(IF=1.376).
40. 2020 Lee JY, Minami Y, Choi BI, Lee WJ, Chou YH, Jeong WK, Park MS, Kudo N, Lee MW, Kamata K, Iijima H, Kim SY, Numata K, Sugimoto K, Maruyama H, Sumino Y, Ogawa C, Kitano M, Joo I, Arita J, Liang JD, Lin HM, Nolsoe C, Gilja OH, **Kudo M**: The AFSUMB consensus statements and recommendations for the clinical practice of contrast-enhanced ultrasound using sonazoid. **Ultrasonography** 39:191-220, 2020(IF=3.075).

2020

英文論文

41. 2020 Lee JY, Minami Y, Choi BI, Lee WJ, Chou YH, Jeong WK, Park MS, Kudo N, Lee MW, Kamata K, Iijima H, Kim SY, Numata K, Sugimoto K, Maruyama H, Sumino Y, Ogawa C, Kitano M, Joo I, Arita J, Liang JD, Lin HM, Nolsoe C, Gilja OH, **Kudo M**: The AFSUMB consensus statements and recommendations for the clinical practice of contrast-enhanced ultrasound using sonazoid. **J Med Ultrasound** 28:59-82, 2020(IF=0.360).
42. 2020 Han G, Berhane S, Toyoda H, Bettinger D, Elshaarawy O, Chan AWH, Kirstein M, Mosconi C, Hucke F, Palmer D, Pinato DJ, Sharma R, Ottaviani D, Jang JW, Labeur TA, van Delden OM, Pirisi M, Stern N, Sangro B, Meyer T, Fateen W, García-Fiñana M, Gomaa A, Waked I, Rewisha E, Aithal GP, Travis S, **Kudo M**, Cucchetti A, Peck-Radosavljevic M, Takkenberg RB, Chan SL, Vogel A, Johnson PJ: Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma: A response-based approach. **Hepatology** 72:198-212, 2020(IF=14.679).
43. 2020 Matsumura M, Komeda Y, Watanabe T, **Kudo M**: Purpura-free small intestinal immunoglobulin A vasculitis complicated by cytomegalovirus reactivation. **BMJ Case Reports** 13:e235042, 2020(IF=0.440).
44. 2020 Yamao K, Takenaka M, Ishikawa R, Okamoto A, Yamazaki T, Nakai A, Omoto S, Kamata K, Minaga K, Matsumoto I, Takeyama Y, Numoto I, Tsurusaki M, Chikugo T, Chiba Y, Watanabe T, **Kudo M**: Partial pancreatic parenchymal atrophy is a new specific finding to diagnose small pancreatic cancer ($\leq 10\text{mm}$) including carcinoma in situ: Comparison with localized benign main pancreatic duct stenosis patients. **Diagnostics** 10:E445, 2020(IF=3.110).
45. 2020 Maeshima S, Ida Y, Shimizu R, Kawaji Y, Tamura T, Nuta J, Hatamaru K, Itonaga M, **Kudo M**, Kitano M: Endoscopic ultrasound-guided radiofrequency ablation of porcine liver. **J Med**

2020

英文論文

- Ultrason** 47:435-443, 2020(IF=0.898).
46. 2020 Minami Y, **Kudo M**: CEUS with sonazoid in HCC diagnosis. **Hepatoma Research** 6:46, 2020. doi: 10.20517/2394-5079.2020.32. (IF=0.000).
47. 2020 Yoshida S, Matsumura M, Maekawa K, Minaga K, Kamata K, Nozawa M, Watanabe T, **Kudo M**: Recurrent abdominal pain caused by nephroptosis. **Clin J Gastroenterol** 13:621-625, 2020 (IF=0.000).
48. 2020 **Kudo M***: A new era of systemic therapy for intermediate and advanced stage hepatocellular carcinoma. **Hepatobil Surg Nutr** 9:530-533, 2020 (IF=5.296).
49. 2020 Zhu AX, Nipp RD, Finn RS, Galle PR, Llovet JM, Blanc JF, Okusaka T, Chau I, Cella D, Girvan A, Gable J, Bowman L, Wang C, Hsu Y, Abada PB, **Kudo M**: Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: Patient-reported outcomes across two randomized clinical trials. **ESMO Open** 5:e000797, 2020 (IF=0.000).
50. 2020 **Kudo M***, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yokosuka O, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson P, Arai Y, on behalf of the TACTICS study group: Randomised, multicentre prospective trial of transarterial chemoembolization (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. **Gut** 69:1492-1501, 2020 (IF=19.819).
51. 2020 Doi T, Fujiwara Y, Koyama T, Ikeda M, Helwig C, Watanabe M, Vugmeyster Y, **Kudo M***: Phase I study of the bifunctional fusion protein bintrafusp alfa in Asian patients with advanced solid tumors, including a hepatocellular carcinoma safety-assessment

2020

英文論文

cohort. **Oncologist** 25:e1292-1302, 2020 (IF=5.025).

52. 2020 Dietrich CF, Nolsoe CP, Barr RG, Berzigotti A, Bums PN, Cantisani V, Chammas MC, Caubal N, Choi BI, Clevert DA, Cui X, Dong Y, D'Onofrio M, Fowlkes JB, Gilja OH, Huang P, Ignee A, Jenssen C, Kono Y, **Kudo M**, Lassau N, Lee WJ, Lee JY, Liang P, Lim A, Lyshchik A, Meloni MF, Correias JM, Minami Y, Moriyasu F, Nicolau C, Piscaglia F, Saftoiu A, Sidhu PS, Sporea I, Torzilli G, Xie X, Zheng R: Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver-update 2020: WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. **Ultraschall in Med** 41:562-585, 2020 (IF=4.966).
53. 2020 Takenaka M, Yoshikawa T, Minaga K, Yamao K, **Kudo M**: A novel teaching tool for visualizing the invisible bile duct axis in 3 dimensions during biliary cannulation (Compact Disc method). **VideoGIE** 5:389-394, 2020 (IF=0.220).
54. 2020 Minaga K, Watanabe T, Hara A, Kamata K, Omoto S, Nakai A, Otsuka Y, Sekai I, Yoshikawa T, Yamao K, Takenaka M, Chiba Y, **Kudo M**: Identification of serum IFN- α and IL-33 as novel biomarkers for type 1 autoimmune pancreatitis and IgG4-related disease. **Sci Rep** 10:14879, 2020 (IF=3.998).
55. 2020 Tsuji N, Umehara Y, Takenaka M, Minami Y, Watanabe T, Nishida N, **Kudo M**: Verrucous antral gastritis in relation to helicobacter pylori infection, nutrition, and gastric atrophy. **Gastroenterol Rep** 8:293-298, 2020 (IF=2.960).
56. 2020 Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, **Kudo M**, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Mamontov K, Meyer T, Kubota T, Dutcus CE, Saito K, Siegel AB, Dubrovsky L, Mody K, Llovet JM: A phase 1b study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. **J Clin Oncol** 38:2960-2970, 2020 (IF=32.956).

2020

英文論文

57. 2020 Dietrich CF, Nolsoe CP, Barr RG, Berzigotti A, Bums PN, Cantisani V, Chammas MC, Caubal N, Choi BI, Clevert DA, Cui X, Dong Y, D'Onofrio M, Fowlkes JB, Gilja OH, Huang P, Ignee A, Jenssen C, Kono Y, **Kudo M**, Lassau N, Lee WJ, Lee JY, Liang P, Lim A, Lyschchik A, Meloni MF, Correias JM, Minami Y, Moriyasu F, Nicolau C, Piscaglia F, Saftoiu A, Sidhu PS, Sporea I, Torzilli G, Xie X, Zheng R: Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver-update 2020: WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. **Ultrasound Med Biol** 46:2579-2604, 2020 (IF=2.514).
58. 2020 Fukami Y, Kaneoka Y, Maeda A, Kumada T, Tanaka J, Aikata T, Kubo S, Izumi N, Kadoya M, Sakamoto M, Nakashima O, Matsuyama Y, Kokudo T, Hasegawa K, Yamashita T, Kashiwabara K, Takayama T, Kokudo N, **Kudo M**, Liver Cancer Study Group of Japan: Liver resection for multiple hepatocellular carcinomas: A Japanese nationwide survey. **Ann Surg** 272:145-154, 2020 (IF=10.130).
59. 2020 Hiraoka A, Kumada T, Tada T, Ogawa C, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Toyoda H, Ohama H, Nouse K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Koizumi Y, Nakamura S, Michitaka K, Hiasa Y, **Kudo M**, On behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan): Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma. **Gastroenterol Rep**: 1-6, 2020 (IF=2.960).
60. 2020 **Kudo M***, Kurosaki M, Ikeda M, Aikata H, Hiraoka A, Torimura T, Sakamoto N, on behalf of Japan Association of Molecular Targeted Therapy for HCC (JAMTT-HCC): Treatment of

2020

英文論文

- hepatocellular carcinoma (HCC) during the COVID-19 outbreak: The working group report of JAMTT-HCC. **Hepatol Res** 50:1004-1014,2020 (IF=3.165).
61. 2020 Yen CJ, **Kudo M**, Lim HY, Hsu CH, Vogel A, Brandi G, Cheng R, Nitu IS, Abada P, Hsu Y, Zhu AX, Kang YK: Efficacy and safety of ramucirumab in Asian and non-Asian patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: pooled individual data analysis of two randomized studies. **Liver Cancer** 9:440-454, 2020 (IF=9.720).
62. 2020 Nishida N, Sakai K, Morita M, Aoki T, Takita M, Hagiwara S, Komeda Y, Takenaka M, Minami Y, Ida H, Ueshima K, Nishio K, **Kudo M**: Association between genetic and immunological background of hepatocellular carcinoma and expression of programmed cell death-1. **Liver Cancer** 9:426-439, 2020 (IF=9.720).
63. 2020 **Kudo M***: A paradigm change in the treatment strategy for hepatocellular carcinoma. **Liver Cancer** 9:367-377, 2020 (IF=9.720).
64. 2020 Takenaka M, Omoto S, **Kudo M**: Endoscopic ultrasound fine-needle biopsy may contribute to the diagnosis of malignant lymph nodes. **Clin Endosc** 53:508-509, 2020 (IF=1.840).
65. 2020 Kamata K, Ashida R, Yasukawa S, Chiba Y, Fukutake N, Nebiki H, Kurita A, Takaoka M, Ogura T, Shiomi H, Asada M, Yasuda H, Shigekawa M, Yanagisawa A, **Kudo M**, Kitano M: Histological diagnosis and grading of pancreatic neuroendocrine tumor by endoscopic ultrasound-guided fine needle biopsy using a 25-gauge needle with a core trap: multicenter prospective trial. **Pancreatology** 20:1428-1433, 2020 (IF=3.629).
66. 2020 Morimoto D, Hyodo T, Kamata K, Kadoba T, Itoh M, Fukushima H, Chiba Y, Takenaka M, Mochizuki T, Ueda Y, Miyagoshi K,

2020

英文論文

- Kudo M**, Ishii K: Navigator-triggered and breath-hold 3D MRCP using compressed sensing: image quality and method selection factor assessment abdominal radiology. **Abdom Radiol** 45:3081-3091, 2020 (IF=2.429).
67. 2020 Chan SL, **Kudo M**: Impacts of COVID-19 on liver cancers and after the pandemic. **Liver Cancer** 9:491-502, 2020 (IF=9.720).
68. 2020 **Kudo M***: Gd-EOB-DTPA-MRI could predict WNT/ β -catenin mutation and resistance to anti-PD-1/PD-L1 therapy in hepatocellular carcinoma. **Liver Cancer** 9:479-490, 2020 (IF=9.720).
69. 2020 Aoki T, **Kudo M***, Ueshima K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Minami Y, Tsurusaki M, Nishida N: Exploratory analysis of lenvatinib therapy in patients with unresectable hepatocellular carcinoma who have failed prior PD-1/PD-L1 checkpoint blockade. **Cancers** 12(10): E3048, 2020. doi: 10.3390/cancers12103048. (IF=6.126)
70. 2020 Ueshima K, Ogasawara S, Ikeda M, Yasui Y, Terashima T, Yamashita T, Obi S, Sato S, Aikata H, Ohmura T, Kuroda H, Ohki T, Nagashima K, Ooka Y, Takita M, Kurosaki M, Chayama K, Kaneko S, Izumi N, Kato N, **Kudo M**, Omata M: Hepatic arterial infusion chemotherapy versus sorafenib in patients with advanced hepatocellular carcinoma. **Liver Cancer** 9:583-595, 2020 (IF=9.720).
71. 2020 **Kudo M***: Recent advances in systemic therapy for hepatocellular carcinoma in an aging society: 2020 update. **Liver Cancer** 9:640-662, 2020 (IF=9.720).
72. 2020 Sakurai T, Nishiyama H, Sakai K, De Velasco MA, Nagai T, Komeda Y, Kashida H, Okada A, Kawai I, Nishio K, Ogata H, **Kudo M**: Mucosal microbiota and gene expression are associated with long-term remission after discontinuation of

2020

英文論文

- adalimumab in ulcerative colitis. **Sci Rep** 10:19186, 2020 (IF=3.998).
73. 2020 **Kudo M**, Galle PR, Llovet JM, Finn R, Vogel A, Motomura K, Assenat E, Merle P, Brandi G, Daniele B, Okusaka T, Tomasek J, Borg C, Dadduzio V, Morimoto M, Pracht M, Jen MH, Ubreva ND, Widau R, Shinozaki K, Yoshikawa R, Zhu AX: Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. **Liver Int** 40:2008-2020, 2020 (IF=5.175).
74. 2020 Sakurai T, Nishida N, **Kudo M**: Promising anticancer therapy: combination of immune checkpoint inhibitors and molecular-targeted agents. **Hepatobil Surg Nutr** 9:777-779, 2020, 2020 (IF=5.296).
75. 2020 Komeda Y, Sakurai T, Sakai K, Morita Y, Hashimoto A, Nagai T, Hagiwara S, Matsumura I, Nishio K, **Kudo M**: Refractory case of ulcerative colitis with idiopathic thrombocytopenic purpura successfully treated by Janus kinase inhibitor tofacitinib: A case report. **World J Clin Cases** 8:6389-6395, 2020 (IF=1.013).
76. 2020 Kariyama K, Nouse K, Hiraoka A, Wakuta A, Oonishi A, Kuzuya T, Toyoda H, Tada T, Tsuji K, Itobayashi E, Ishikawa T, Takaguchi K, Tsutsui A, Shimada N, **Kudo M**, Kumada T, RELPEC Study Group and HCC 48 Group: EZ-ALBI score for predicting hepatocellular carcinoma prognosis. **Liver Cancer** 9:734-743, 2020 (IF=9.720).
77. 2020 **Kudo M***: Limited impact of anti-PD-1/PD-L1 monotherapy for hepatocellular carcinoma. **Liver Cancer** 9:629-639, 2020 (IF=9.720).
78. 2020 Nishida N, **Kudo M**: Artificial intelligence in medical imaging and its application in sonography for the management of liver tumor. **Front Oncol** 10:594580, 2020 (IF=4.848).

2020

英文論文

79. 2020 Masaki S, Watanabe T, Minaga K, Kamata K, Komeda Y, Kimura M, **Kudo M**: Possible involvement of autophagy in esophageal ulcers in anorexia nervosa. **Clin J Gastroenterol** 13:473-476, 2020 (IF=0.000).
80. 2020 Ladrón de Guevara L, Dagher L, Arruda VMV, Nakajima K, **Kudo M**: Sorafenib treatment by Child–Pugh score in Mexican and South American patients with hepatocellular carcinoma. **Future Oncol** 16:2511-2520, 2020 (IF=2.660).
81. 2020 Yoshida A, Minaga K, Takeda O, Hanno H, Takayanagi S, Dozaiku T, **Kudo M**: Successful biliary cannulation using a novel rotatable sphincterotome in a patient with situs inversus totalis. **Endoscopy** 52:E333-E334, 2020 (IF=7.341).
82. 2020 Minaga K, Takenaka M, Ogura T, Tamura T, Kuroda T, Kaku T, Uenoyama Y, Noguchi C, Nishikiori H, Imai H, Sagami R, Fujimori N, Higuchi K, **Kudo M**, Chiba Y, Kitano M: Endoscopic ultrasound-guided biliary drainage for malignant biliary obstruction with surgically altered anatomy: A multicenter prospective registration Study. **Ther Adv Gastroenter** 13:1756284820930964, 2020 (IF=3.520).
83. 2020 Kamata K, Watanabe T, Minaga K, Hara A, Sekai I, Otsuka Y, Yoshikawa T, Park AM, **Kudo M**: Gut microbiome alterations in type 1 autoimmune pancreatitis after induction of remission by prednisolone. **Clin Exp Immunol** 202:308-320, 2020 (IF=3.532).
84. 2020 **Kudo M***, Morimoto M, Moriguchi M, Izumi N, Takayama T, Yoshiji H, Hino K, Oikawa T, Chiba T, Motomura K, Kato J, Yasuchika K, Ido A, Sato T, Ikawa Y, Ueshima K, Ikeda M, Okusaka T, Tamura K, Furuse J: A randomized, double-blind, placebo-controlled, phase III study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma. **Cancer Sci** 111(10):3759-3769, 2020 (IF=6.716).

2020

英文論文

85. 2020 Yamao K, Takenaka M, Ogura T, Hashimoto H, Matsumoto H, Yamamoto M, Ikeura T, Kurita A, Li ZL, Shiomi H, Chiba Y, **Kudo M**, Sanuki T: Utility and safety of a novel fully covered metal stent in unresectable distal malignant biliary obstruction. **Digest Dis Sci** 65:3702-3709, 2020 (IF=3.199).